A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 285 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR A vision for the next decade of UK life sciences July 21, 2021 Some Children with Liver Cancer May Need Less Chemotherapy, Study Suggests May 9, 2019 Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and... December 17, 2024 FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive,... Mother and Son with Shared BRCA Gene Mutation Go Through Cancer... Coping With Social Isolation as a Teen With Cancer
